Elevance Health Plunges 8.29% on Earnings Miss

On July 17, 2025, Elevance Health's stock price dropped by 8.29% in pre-market trading.

Elevance Health reported its second-quarter 2025 financial results, revealing an operating revenue of $18.1 billion, an operating gain of $0.9 billion, and an adjusted operating gain of $0.9 billion. The company's operating margin stood at 5.2%.

Despite these figures, Elevance Health's earnings per share (EPS) for the quarter missed analyst estimates by $0.23, coming in at $8.84 instead of the expected $9.07. The company's revenue for the quarter was $49.4 billion.

Elevance Health has projected its full-year 2025 EPS to be $30.00, which is lower than the analyst consensus of $34.48. This projection, along with the earnings miss, has contributed to the stock's decline.

Elevance Health's financial results come at a time when other major health insurers, such as UnitedHealth Group and Centene Corp, have also faced challenges in managing costs and providing guidance for the year. This sector-wide uncertainty has likely added to the pressure on Elevance Health's stock price.